New hope for myeloma patients: epunamin combo under study

This study is testing whether adding the drug epunamin to a standard chemotherapy regimen (DECP) can help people with relapsed or refractory multiple myeloma, a type of blood cancer that has not responded to previous treatments. The study will enroll 48 adults aged 18 to 75 and track how many achieve a meaningful reduction in cancer cells after four treatment cycles. It is a real-world study, meaning it observes what happens in everyday clinical practice rather than in a strictly controlled lab setting.